Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Valneva SE Pref.

Market Cap 437M 500M 404M 377M 708M 47.28B 714M 4.8B 1.87B 23.24B 1.88B 1.84B 80.75B P/E 2026 *
-6.28x
P/E 2027 * 6.07x
Enterprise Value 565M 647M 523M 488M 916M 61.12B 923M 6.21B 2.42B 30.05B 2.43B 2.38B 104B EV / Sales 2026 *
3.72x
EV / Sales 2027 * 1.69x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 500M
+2.92%+3.80%-8.52%-3.13% 43.24B
+1.73%+3.59%+318.08%+564.04% 35.25B
+0.61%+1.34%+10.00%+46.20% 30.22B
+0.02%-5.93%+8.45%-21.44% 28.01B
-1.06%-3.71%+9.08%+19.56% 24.08B
-1.23%+2.11% - - 14.16B
-0.99%-2.53%+47.29%+102.88% 13.01B
+2.11%+3.35%+8.90%+14.56% 12.7B
+2.39%+2.61%+102.86%+84.20% 12.54B
Average +0.35%-0.27%+62.02%+100.86% 23.69B
Weighted average by Cap. +0.48%-0.20%+68.43%+118.53%

Financials

2026 *2027 *
Net sales 152M 174M 140M 131M 246M 16.42B 248M 1.67B 649M 8.07B 652M 638M 28.04B 294M 337M 272M 254M 477M 31.8B 480M 3.23B 1.26B 15.63B 1.26B 1.24B 54.31B
Net income -66.01M -75.55M -61.06M -56.99M -107M -7.14B -108M -726M -282M -3.51B -284M -277M -12.19B 70.5M 80.68M 65.21M 60.87M 114M 7.62B 115M 775M 302M 3.75B 303M 296M 13.02B
Net Debt 128M 147M 118M 111M 207M 13.84B 209M 1.41B 547M 6.81B 550M 538M 23.65B 60.02M 68.69M 55.52M 51.82M 97.27M 6.49B 97.99M 660M 257M 3.19B 258M 252M 11.09B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.305EUR
Average target price
5.233EUR
Spread / Average Target
+127.04%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!